Oligomeric and fibrillar amyloid beta 42 induce platelet aggregation partially through GPVI

Platelets

Volumn 29, Issue 4, 2018, Pages 415-420

  Elaskalani, O ^a   Khan, I ^a   Morici, M ^b   Matthysen, C ^a   Sabale, M ^a   Martins, R N ^a,c   Verdile, G ^a,b,d   Metharom, P ^a  

^a CURTIN UNIVERSITY   (Australia)

^b EDITH COWAN UNIVERSITY   (Australia)

^c MACQUARIE UNIVERSITY   (Australia)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Amyloid beta; platelet aggregation

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; OLIGOMER; PROTEIN KINASE B; THROMBOCYTE RECEPTOR; THROMBOCYTE RECEPTOR GPVI; UNCLASSIFIED DRUG; AMYLOID BETA PROTEIN;

ARTICLE; ATOMIC FORCE MICROSCOPY; CELL FUNCTION; DEGRANULATION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; NEUROTOXICITY; NORMAL HUMAN; OLIGOMERIZATION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; BLOOD CLOTTING PARAMETERS; METABOLISM; PHYSIOLOGY; PROCEDURES;

AMYLOID BETA-PEPTIDES; HUMANS; PLATELET AGGREGATION; PLATELET FUNCTION TESTS;

EID: 85036641685     PISSN: 09537104     EISSN: 13691635     Source Type: Journal    
DOI: 10.1080/09537104.2017.1401057     Document Type: Article

References (60)

1. Roher AE, Esh CL, Kokjohn TA, Castaño EM, Van Vickle GD, Kalback WM, Patton RL, Luehrs DC, Daugs ID, Kuo Y-M, Emmerling MR, Soares H, Quinn JF, Kaye J, Connor DJ, Silverberg NB, Adler CH, Seward JD, Beach TG, Sabbagh MN., Kuo YM and others. Amyloid beta peptides in human plasma and tissues and their significance for Alzheimer’s disease. Alzheimer’s & Dementia 2009;5(1):18–29. doi:10.1016/j.jalz.2008.10.004.
2. Chen M, Inestrosa NC, Ross GS, Fernandez HL. Platelets are the principal cource of amyloid beta peptide in human blood. Biochem Biophyis Res Commun 1995;213.
3. Rosenberg RN, Baskin F, Fosmire JA, Risser R, Adams P, Svetlik D, Honig LS, Cullum CM, Weiner MF. Altered amyloid protein processing in platelets of patients with Alzheimer disease. Arch Neurol 1997;54(2):139–144.
4. Zainaghi IA, Talib LL, Diniz BS, Gattaz WF, Forlenza OV. Reduced platelet amyloid precursor protein ratio (APP ratio) predicts conversion from mild cognitive impairment to Alzheimer’s disease. J Neural Transm (Vienna) 2012;119(7):815–819.
5. Chatterjee P, Gupta VB, Fagan AM, Jasielec MS, Xiong C, Sohrabi HR, Dhaliwal S, Taddei K, Bourgeat P. Brown BM and others. Decreased platelet APP isoform ratios in autosomal dominant Alzheimer’s disease: baseline data from a DIAN cohort subset. Curr Alzheimer Res 2015;12(2):157–164.
6. Skoog I, Davidsson P, Aevarsson O, Vanderstichele H, Vanmechelen E, Blennow K. Cerebrospinal fluid beta-amyloid 42 is reduced before the onset of sporadic dementia: a population-based study in 85-year-olds. Dement Geriatr Cogn Disord 2003;15(3):169–176.
7. Gustafson DR, Skoog I, Rosengren L, Zetterberg H, Blennow K. Cerebrospinal fluid beta-amyloid 1-42 concentration may predict cognitive decline in older women. J Neurol Neurosurg Psychiatry 2007;78(5):461–464.
8. Stomrud E, Hansson O, Blennow K, Minthon L, Londos E. Cerebrospinal fluid biomarkers predict decline in subjective cognitive function over 3 years in healthy elderly. Dement Geriatr Cogn Disord 2007;24(2):118–124.
9. Mayeux R, Honig LS, Tang MX, Manly J, Stern Y, Schupf N, Mehta PD. Plasma A[beta]40 and A[beta]42 and Alzheimer’s disease: relation to age, mortality, and risk. Neurology 2003;61(9):1185–1190.
10. Mayeux R, Tang M-X, Jacobs DM, Manly J, Bell K, Merchant C, Small SA, Stern Y, Wisniewski HM, Mehta PD, Mayeux R, Tang MX, Jacobs DM, Manly J, Bell K, Merchant C, Small SA, Stern Y, Wisniewski HM, Mehta PD. Plasma amyloid ? peptide 1-42 and incipient Alzheimer’s disease. Ann Neurol 1999;46(3):412–416. doi:10.1002/(ISSN)1531-8249.
11. Lui JK, Laws SM, Li QX, Villemagne VL, Ames D, Brown B, Bush AI, De Ruyck K, Dromey J. Ellis KA and others. Plasma amyloid-beta as a biomarker in Alzheimer’s disease: the AIBL study of aging. J Alzheimers Dis 2010;20(4):1233–1242.
12. Graff-Radford NR, Crook JE, Lucas J, Boeve BF, Knopman DS, Ivnik RJ, Smith GE, Younkin LH, Petersen RC, Younkin SG. Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. Arch Neurol 2007;64(3):354–362.
13. Blennow K, De Meyer G, Hansson O, Minthon L, Wallin A, Zetterberg H, Lewczuk P, Vanderstichele H, Vanmechelen E. Kornhuber J and others. Evolution of Abeta42 and Abeta40 levels and Abeta42/Abeta40 ratio in plasma during progression of Alzheimer’s disease: a multicenter assessment. J Nutr Health Aging 2009;13(3):205–208.
14. Yaffe K, Weston A, Graff-Radford NR, Satterfield S, Simonsick EM, Younkin SG, Younkin LH, Kuller L, Ayonayon HN. Ding J and others. Association of plasma beta-amyloid level and cognitive reserve with subsequent cognitive decline. Jama 2011;305(3):261–266.
15. Shen MY, Chen FY, Hsu JF, Fu RH, Chang CM, Chang CT, Liu CH, Wu JR, Lee AS. Chan HC and others. Plasma L5 levels are elevated in ischemic stroke patients and enhance platelet aggregation. Blood 2016;127(10):1336–1345.
16. Moulin S, Leys D, Schraen-Maschke S, Bombois S, Mendyk AM, Muhr-Tailleux A, Cordonnier C. Abeta1-40 and Abeta1-42 plasmatic levels in stroke: influence of pre-existing cognitive status and stroke characteristics. Curr Alzheimer Res 2017;14(6):686–694.
17. Marti-Fabregas J, Delgado-Mederos R, Marin R. de la Ossa NP, Alonso de Lecinana M, Rodriguez-Yanez M, Sanahuja J, Purroy F, De Arce AM, Carrera D and others. Prognostic value of plasma beta-amyloid levels in patients with acute intracerebral hemorrhage. Stroke 2014;45(2):413–417.
18. Peters KE, Davis WA, Taddei K, Martins RN, Masters CL, Davis TM, Bruce DG. Plasma amyloid-beta peptides in type 2 diabetes: A Matched Case-Control Study. J Alzheimers Dis 2017;56(3):1127–1133.
19. Van Etten ES, Verbeek MM, Van Der Grond J, Zielman R, Van Rooden S, Van Zwet EW, Van Opstal AM, Haan J, Greenberg SM. van Buchem MA and others. beta-Amyloid in CSF: biomarker for preclinical cerebral amyloid angiopathy. Neurology 2017;88(2):169–176.
20. Noguchi-Shinohara M, Komatsu J, Samuraki M, Matsunari I, Ikeda T, Sakai K, Hamaguchi T, Ono K, Nakamura H, Yamada M. Cerebral amyloid angiopathy-related microbleeds and cerebrospinal fluid biomarkers in Alzheimer’s disease. J Alzheimer’s Dis JAD 2017;55(3):905–913.
21. Kniewallner KM, Ehrlich D, Kiefer A, Marksteiner J, Humpel C. Platelets in the Alzheimer’s disease brain: do they play a role in cerebral amyloid angiopathy?. Curr Neurovasc Res 2015;12(1):4–14.
22. Gowert NS, Donner L, Chatterjee M, Eisele YS, Towhid ST, Munzer P, Walker B, Ogorek I, Borst O. Grandoch M and others. Blood platelets in the progression of Alzheimer’s disease. PLoS One 2014;9(2):e90523.
23. Jarre A, Gowert NS, Donner L, Munzer P, Klier M, Borst O, Schaller M, Lang F, Korth C, Elvers M. Pre-activated blood platelets and a pro-thrombotic phenotype in APP23 mice modeling Alzheimer’s disease. Cell Signal 2014;26(9):2040–2050.
24. Canobbio I, Guidetti GF, Oliviero B, Manganaro D, Vara D, Torti M, Pula G. Amyloid beta-peptide-dependent activation of human platelets: essential role for Ca2+ and ADP in aggregation and thrombus formation. Biochem J 2014;462(3):513–523.
25. Canobbio I, Catricala S, Di Pasqua LG, Guidetti G, Consonni A, Manganaro D, Torti M. Immobilized amyloid Abeta peptides support platelet adhesion and activation. FEBS Lett 2013;587(16):2606–2611.
26. Herczenik E, Bouma B, Korporaal SJ, Strangi R, Zeng Q, Gros P, Van Eck M, Van Berkel TJ, Gebbink MF, Akkerman JW. Activation of human platelets by misfolded proteins. Arterioscler Thromb Vasc Biol 2007;27(7):1657–1665.
27. Shen MY, Hsiao G, Fong TH, Chen HM, Chou DS, Lin CH, Sheu JR, Hsu CY. Amyloid beta peptide-activated signal pathways in human platelets. Eur J Pharmacol 2008;588(2–3):259–266.
28. Shen MY, Hsiao G, Fong TH, Chou DS, Sheu JR. Expression of amyloid beta peptide in human platelets: pivotal role of the phospholipase Cgamma2-protein kinase C pathway in platelet activation. Pharmacol Res 2008;57(2):151–158.
29. Sonkar VK, Kulkarni PP, Dash D. Amyloid beta peptide stimulates platelet activation through RhoA-dependent modulation of actomyosin organization. Faseb J 2014;28(4):1819–1829.
30. Donner L, Falker K, Gremer L, Klinker S, Pagani G, Ljungberg LU, Lothmann K, Rizzi F, Schaller M. Gohlke H and others. Platelets contribute to amyloid-beta aggregation in cerebral vessels through integrin alphaIIbbeta3-induced outside-in signaling and clusterin release. Sci Signal 2016;9(429):ra52.
31. Stine WB, Jungbauer L, Yu C, LaDu MJ. Preparing synthetic Abeta in different aggregation states. Methods Mol Biol 2011;670:13–32.
32. Barr RK, Verdile G, Wijaya LK, Morici M, Taddei K, Gupta VB, Pedrini S, Jin L, Nicolazzo JA. Knock E and others. Validation and characterization of a novel peptide that binds monomeric and aggregated beta-amyloid and inhibits the formation of neurotoxic oligomers. J Biol Chem 2016;291(2):547–559.
33. Nečas D, Gwyddion: KP. an open-source software for SPM data analysis. Cent Eur J Phys 2012;10(1):181–188.
34. Abdol Razak N, Elaskalani O, Pancreatic Cancer-Induced MP. Neutrophil extracellular traps: A potential contributor to cancer-associated thrombosis. Int J Mol Sci 2017;18(3):487.
35. Taddei K, Laws SM, Verdile G, Munns S, D’Costa K, Harvey AR, Martins IJ, Hill F, Levy E. Shaw JE and others. Novel phage peptides attenuate beta amyloid-42 catalysed hydrogen peroxide production and associated neurotoxicity. Neurobiol Aging 2010;31(2):203–214.
36. Schmitz O, Brock B, Rungby J. Amylin agonists: a novel approach in the treatment of diabetes. Diabetes 2004;53(Suppl 3):S233–8.
37. Taylor L, Vasudevan SR, Jones CI, Gibbins JM, Churchill GC, Campbell RD, Coxon CH. Discovery of novel GPVI receptor antagonists by structure-based repurposing. PLoS One 2014;9(6):e101209.
38. Jiang P, Loyau S, Tchitchinadze M, Ropers J, Jondeau G, Jandrot-Perrus M. Inhibition of Glycoprotein VI clustering by collagen as a mechanism of inhibiting collagen-induced platelet responses: the example of losartan. PLoS One 2015;10(6):e0128744.
39. Kim S, Jin J, Kunapuli SP. Akt Activation in platelets depends on Gi signaling pathways. J Biol Chem 2004;279(6):4186–4195.
40. Dahlgren KN, Manelli AM, Stine WB, Jr., Baker LK, Krafft GA, LaDu MJ. Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability. J Biol Chem 2002;277(35):32046–32053.
41. Roher AE, Debbins JP, Malek-Ahmadi M, Chen K, Pipe JG, Maze S, Belden C, Maarouf CL, Thiyyagura P. Mo H and others. Cerebral blood flow in Alzheimer’s disease. Vasc Health Risk Manag 2012;8:599–611.
42. Aronson MK, Ooi WL, Morgenstern H, Hafner A, Masur D, Crystal H, Frishman WH, Fisher D, Women KR. myocardial infarction, and dementia in the very old. Neurology 1990;40(7):1102–1106.
43. Soneira CF, Scott TM. Severe cardiovascular disease and Alzheimer’s disease: senile plaque formation in cortical areas. Clin Anat 1996;9(2):118–127.
44. Sparks DL, Hunsaker JC, 3rd, Scheff SW, Kryscio RJ, Henson JL, Markesbery WR. Cortical senile plaques in coronary artery disease, aging and Alzheimer’s disease. Neurobiol Aging 1990;11(6):601–607.
45. Stellos K, Katsiki N, Tatsidou P, Bigalke B, Laske C. Association of platelet activation with vascular cognitive impairment: implications in dementia development?. Curr Vasc Pharmacol 2014;12(1):152–154.
46. Mazereeuw G, Herrmann N, Xu H, Figeys D, Oh PI, Bennett SA, Lanctot KL. Platelet-activating factors are associated with cognitive deficits in depressed coronary artery disease patients: a hypothesis-generating study. J Neuroinflammation 2014;11:119.
47. Prodan CI, Ross ED, Vincent AS, Dale GL. Rate of progression in Alzheimer’s disease correlates with coated-platelet levels–a longitudinal study. Transl Res 2008;152(3):99–102.
48. Prodan CI, Ross ED, Stoner JA, Cowan LD, Vincent AS, Dale GL. Coated-platelet levels and progression from mild cognitive impairment to Alzheimer disease. Neurology 2011;76(3):247–252.
49. Stellos K, Panagiota V, Kogel A, Leyhe T, Gawaz M, Laske C. Predictive value of platelet activation for the rate of cognitive decline in Alzheimer’s disease patients. J Cereb Blood Flow Metab 2010;30(11):1817–1820.
50. Sevush S, Jy W, Horstman LL, Mao W, Kolodny L, Ahn YS. PLatelet activation in alzheimer disease. Arch Neurol 1998;55(4):530–536.
51. Ciabattoni G, Porreca E, Di Febbo C, Di Iorio A, Paganelli R, Bucciarelli T, Pescara L, Del Re L, Giusti C. Falco A and others. Determinants of platelet activation in Alzheimer’s disease. Neurobiol Aging 2007;28(3):336–342.
52. Canobbio I, Visconte C, Oliviero B, Guidetti G, Zara M, Pula G, Torti M. Increased platelet adhesion and thrombus formation in a mouse model of Alzheimer’s disease. Cell Signal 2016;28(12):1863–1871.
53. Bermejo P, Martín-Aragón S, Benedí J, Susín C, Felici E, Gil P, Ribera JM, Villar ÁM. Differences of peripheral inflammatory markers between mild cognitive impairment and Alzheimer’s disease. Immunol Lett 2008;117(2):198–202.
54. Purandare N, Burns A, Daly KJ, Hardicre J, Morris J, Macfarlane G, McCollum C. Cerebral emboli as a potential cause of Alzheimer’s disease and vascular dementia: case-control study. Bmj 2006;332(7550):1119–1124.
55. Bell RD, Winkler EA, Singh I, Sagare AP, Deane R, Wu Z, Holtzman DM, Betsholtz C, Armulik A. Sallstrom J and others. Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. Nature 2012;485(7399):512–516.
56. Sagare AP, Bell RD, Zhao Z, Ma Q, Winkler EA, Ramanathan A, Zlokovic BV. Pericyte loss influences Alzheimer-like neurodegeneration in mice. Nat Commun 2013;4:2932.
57. Thornton P, McColl BW, Greenhalgh A, Denes A, Allan SM, Rothwell NJ. Platelet interleukin-1alpha drives cerebrovascular inflammation. Blood 2010;115(17):3632–3639.
58. Hohsfield LA, Humpel C. Migration of blood cells to β-amyloid plaques in Alzheimer’s disease. Exp Gerontol 2015;65:8–15.
59. Pietronigro EC, Della Bianca V, Zenaro E, Constantin G. NETosis in Alzheimer’s Disease. Front Immunol 2017;8:211.
60. Alshehri OM, Montague S, Watson S, Carter P, Sarker N, Manne BK, Miller JL, Herr AB, Pollitt AY. O’Callaghan CA and others. Activation of glycoprotein VI (GPVI) and C-type lectin-like receptor-2 (CLEC-2) underlies platelet activation by diesel exhaust particles and other charged/hydrophobic ligands. Biochem J 2015;468(3):459–473.